Alpha Cognition Enhances Investor Relations for Alzheimer’s Drug

Alpha Cognition Inc (TSE:ACOG) has released an update.

Alpha Cognition Inc., a biopharmaceutical company targeting neurodegenerative diseases, has partnered with Stonegate Capital Partners to boost its investor relations, particularly within the U.S. investor community. The collaboration, involving a monthly fee with an initial six-month term, is aimed at expanding the company’s shareholder base. This strategic move comes as Alpha Cognition advances the development of ALPHA-1062, a novel treatment for Alzheimer’s disease with a focus on reducing gastrointestinal side effects.

For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.